Study Summary
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
Interested in this trial?
Submit an InquiryInterventions
Novel CAR-TBIOLOGICAL
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hunan Provincial People's Hospital | Changsha | Hunan | China |